Analysis shows that the biomedical field is becoming more and more inefficient
What should the cautious scientists focus on next? Is it a boring but safe experiment that will certainly produce a paper, or is it possible to experiment with a lunar probe like a lunar probe that will have nothing to gain but if it succeeds?
This problem has plagued researchers with limited time and funding. In order to find out, a study published in the Proceedings of the National Academy of Sciences recently analyzed some hard data. Although researchers can't provide a foolproof secret to success, they do offer some thought-provoking things.
This study analyzes the risks and rewards in the biomedical sciences. Researchers are concerned with the growing knowledge of how large numbers of molecules involved in biological pathways work and interact. To this end, they screened millions of US patents and abstracts from online medical literature analysis and retrieval systems to find all references related to chemicals in life, including known molecules such as DNA and RNA. Metabolic molecules, neuropeptides, hormones.
The researchers then followed up on 50,000 molecules from the 1980s and turned them into a web map of biomedical knowledge. If two molecules are often mentioned in a single paper, they will be connected on the map. If the two molecules are never mentioned in the same paper, they will not be linked on the map.
As time went by, scientists discovered an ever-increasing connection between molecules. However, how effectively did they discover this complex network? Finding an answer requires a supercomputer, a mathematical model for the discovery process, and a simulation of the many different possible choices for which experiment and its results.
Overall, the study concluded that the biomedical field is becoming inefficient as time goes by, and the possibility of new research revealing new territories of biomedical networks is becoming smaller. This finding suggests that a more optimized strategy is to allow researchers to take on more risky work as the field matures.
(Jilin Qijian Biotechnology Co., Ltd. www.qjbio.com.cn)